Ashland Inc. Reports $16 Million Net Income and 7.3% Revenue Growth for Quarter Ended June 30, 2026

Ashland Inc. reported a net income of $16 million, or $0.35 per diluted share, for the three months ended June 30, 2026, a significant recovery from a net loss of $742 million, or a loss of $15.70 per diluted share, in the same period last year. The company’s revenue for the quarter increased by 7.3% to $497 million, compared to $463 million in the prior year, driven by higher sales volumes and favorable foreign currency exchange rates. For the nine months ended June 30, 2026, Ashland's revenue rose to $1.365 billion from $1.347 billion, reflecting a year-over-year increase of 1.3%.

The financial performance showed notable improvements compared to the previous fiscal period, particularly in operating income, which reached $43 million, a turnaround from a loss of $708 million in the same quarter last year. This improvement was largely attributed to the absence of a significant goodwill impairment charge that had impacted the previous year’s results, as well as better cost management and increased sales. Adjusted EBITDA for the quarter was reported at $109 million, slightly down from $113 million in the prior year, primarily due to higher production costs and increased selling, general, and administrative expenses.

Strategically, Ashland has been focusing on restructuring and optimizing its operations. The company initiated a $30 million pre-tax restructuring plan aimed at enhancing profitability and has made progress in its multi-year manufacturing network optimization, which is expected to yield pre-tax savings of $50 million to $55 million. Additionally, Ashland completed the sale of excess corporate real estate, contributing to its income on divestitures. The company continues to monitor its portfolio and has made adjustments to its operations in response to market conditions.

Operationally, Ashland reported a total employee headcount of approximately 2,900, serving customers in over 100 countries. The company’s sales outside of North America accounted for 73% of total sales for both the three and nine months ended June 30, 2026. The Life Sciences segment, which includes pharmaceuticals and nutrition, generated $180 million in sales for the quarter, up from $162 million in the prior year, while the Personal Care segment also saw growth, reaching $155 million compared to $147 million. The Specialty Additives segment reported $136 million in sales, a slight increase from $131 million.

Looking ahead, Ashland reaffirmed its full-year fiscal 2026 sales guidance of $1.835 to $1.870 billion and its Adjusted EBITDA guidance of $385 to $400 million. However, the company revised its adjusted EPS outlook to low-to-mid-single-digit growth, reflecting a higher tax rate associated with unfavorable discrete items. Despite ongoing macroeconomic challenges, Ashland remains optimistic about growth in its core markets, particularly in Life Sciences and Personal Care, and anticipates continued momentum from recent pricing actions and operational improvements.